Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study investigates potential protective effect of atorvastatin pre-treatment in patient
with stable coronary artery disease undergoing percutaneous coronary intervention (PCI).
Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two
days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is
myocardial infarction measured by troponin I and creatine kinase myocardial band.